Department of Surgical Oncology, Hospital Oost-Limburg, Genk, Belgium.
Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands.
Eur J Surg Oncol. 2021 Jan;47(1):11-35. doi: 10.1016/j.ejso.2020.02.012. Epub 2020 Feb 28.
Pseudomyxoma Peritonei (PMP) is a rare peritoneal malignancy, most commonly originating from a perforated epithelial tumour of the appendix. Given its rarity, randomized controlled trials on treatment strategies are lacking, nor likely to be performed in the foreseeable future. However, many questions regarding the management of appendiceal tumours, especially when accompanied by PMP, remain unanswered. This consensus statement was initiated by members of the Peritoneal Surface Oncology Group International (PSOGI) Executive Committee as part of a global advisory role in the management of uncommon peritoneal malignancies. The manuscript concerns an overview and analysis of the literature on mucinous appendiceal tumours with, or without, PMP. Recommendations are provided based on three Delphi voting rounds with GRADE-based questions amongst a panel of 80 worldwide PMP experts.
腹膜假黏液瘤(PMP)是一种罕见的腹膜恶性肿瘤,最常见于阑尾穿孔的上皮性肿瘤。由于其罕见性,缺乏关于治疗策略的随机对照试验,在可预见的未来也不太可能进行。然而,关于阑尾肿瘤的管理,特别是当伴有 PMP 时,仍有许多问题尚未得到解答。本共识声明由腹膜表面肿瘤国际组织(PSOGI)执行委员会的成员发起,作为其在罕见腹膜恶性肿瘤管理方面全球咨询作用的一部分。本文涉及对伴有或不伴有 PMP 的黏液性阑尾肿瘤的文献进行综述和分析。根据对 80 名全球 PMP 专家进行的三轮 Delphi 投票和基于 GRADE 的问题,提出了建议。